Stevanato Group S.p.A. (STVN)
| Market Cap | 5.70B |
| Revenue (ttm) | 1.22B |
| Net Income (ttm) | 127.92M |
| Shares Out | 272.90M |
| EPS (ttm) | 0.48 |
| PE Ratio | 43.99 |
| Forward PE | 36.76 |
| Dividend | $0.06 (0.28%) |
| Ex-Dividend Date | Jun 4, 2024 |
| Volume | 168,750 |
| Open | 20.49 |
| Previous Close | 20.47 |
| Day's Range | 20.32 - 21.32 |
| 52-Week Range | 16.56 - 34.00 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 27.50 (+31.58%) |
| Earnings Date | Mar 6, 2025 |
About STVN
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines,... [Read more]
Financial Performance
In 2023, Stevanato Group's revenue was 1.09 billion, an increase of 10.34% compared to the previous year's 983.68 million. Earnings were 145.63 million, an increase of 1.95%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for STVN stock is "Buy." The 12-month stock price forecast is $27.5, which is an increase of 31.58% from the latest price.
News
Stevanato Group to Present at Upcoming Investor Conference
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences...
Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement
Q3 2024 sales exceeded estimates, but adj. EBITDA and EPS fell short due to under-utilization and higher costs in the Engineering division. Despite temporary headwinds, we expect sequential margin imp...
Stevanato Group to Present at Upcoming Investor Conferences
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences...
Stevanato Group S.p.A. (STVN) Q3 2024 Earnings Call Transcript
Stevanato Group S.p.A. (NYSE:STVN) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Lisa Miles - Senior Vice President & Investor Relations Franco Stevanato - Chairma...
Stevanato Group Reports Financial Results for the Third Quarter of 2024
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology a...
Stevanato Group Will Introduce Its Large-Volume Vertiva® 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI Milan
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences ...
Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU”
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology a...
Stevanato Group S.p.A. (STVN) Q2 2024 Earnings Call Transcript
Stevanato Group S.p.A. (STVN) Q2 2024 Earnings Call Transcript
Stevanato Group Reports Financial Results for the Second Quarter of 2024
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Report Second Quarter 2024 Financial Results on August 6, 2024
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology a...
Stevanato Being Investigated on Behalf of Stevanato Group S.p.A. Investors.
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations...
An Investigation Has Commenced on Behalf of Stevanato Group S.p.A. Shareholders.
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violation...
Stevanato Group Unveils New Plant in Cisterna di Latina for the Production of Pre-Sterilized EZ-fill® Syringes and Cartridges
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology ...
Stevanato: Destock Pressures, Long-Term Upside
Stevanato revised its guidance for 2024 due to weaker-than-expected orders and clients' destocking activities. The company's Q1 results show decreased EBITDA and profit, causing investors to sell off ...
Stevanato Group Appoints Franco Stevanato Chief Executive Officer, Succeeding Franco Moro
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology a...
Stevanato Group Announces Results of Annual General Meeting
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology a...
Stevanato Group S.p.A. (STVN) Q1 2024 Earnings Call Transcript
Stevanato Group S.p.A. (NYSE:STVN) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Lisa Miles – Investor Relations Franco Stevanato – Executive Chairman Marco Dal Lago – ...
Stevanato Group Reports Financial Results for the First Quarter of 2024
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Present at the Bank of America Securities Healthcare Conference
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
International Companies Drive Diabesity Innovation
The diabetes and obesity markets are large and growing, with an estimated total long-term addressable market of $100 billion in the US alone. Denmark's Novo Nordisk and US-based Eli Lilly are leading ...
Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters' Option to Purchase Additional Ordinary Shares
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions ...
Stevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions ...
Stevanato Group Announces Public Offering of Ordinary Shares
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions ...